CVS raised full-year 2026 adjusted EPS guidance to $7.90-$8.10 and lifted cash flow outlook to at least $11.5 billion.
CVS provided an early 2027 adjusted EPS floor of at least $8.44, implying continued enterprise earnings expansion.
CVS will launch a new Eli Lilly cash-pay GLP-1 access pathway later in 2026 for Zepbound and Foundayo patients.
CVS plans to launch the Health100 AI-native consumer engagement platform later in 2026.
CVS will transition commercial template formularies away from branded STELARA to lower-cost biosimilars on July 1, 2026.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for CVS Health Corp. and 4,900+ companies.